MedTrace Logo

Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism

NCT00990704 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2011-07-11

Study results available
· View outcomes & findings →

Summary

This study is a exploratory comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in chronic kidney disease participants receiving hemodialysis with secondary hyperparathyroidism.

Conditions

  • Secondary Hyperparathyroidism
  • Hemodialysis

Interventions

DRUG

paricalcitol

Intravenous administration 3 times a week immediately before completion of dialysis

DRUG

maxacalcitol

Intravenous administration 3 times a week immediately before completion of dialysis

Sponsors & Collaborators

Principal Investigators

  • Moriaki Kubo · Abbott Japan Co.,Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00990704 on ClinicalTrials.gov